Halozyme Therapeutics (NASDAQ:HALO) updated its FY 2020
Pre-Market earnings guidance on Tuesday. The company provided earnings per share guidance of 0.60-0.75 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.56. The company issued revenue guidance of $230-245 million, compared to the consensus revenue estimate of $227.01 million.Halozyme Therapeutics also updated its FY 2019
Pre-Market guidance to EPS.
Several research firms have recently weighed in on HALO. BidaskClub lowered Halozyme Therapeutics from a hold rating to a sell rating in a research note on Wednesday, January 1st. Goldman Sachs Group began coverage on Halozyme Therapeutics in a research note on Wednesday, January 8th. They set a buy rating and a $24.00 price objective for the company. BMO Capital Markets raised Halozyme Therapeutics from a market perform rating to an outperform rating and raised their price objective for the stock from $17.00 to $24.00 in a research note on Thursday, January 9th. ValuEngine lowered Halozyme Therapeutics from a hold rating to a sell rating in a research note on Friday, January 10th. Finally, Barclays raised Halozyme Therapeutics from an underweight rating to an equal weight rating and reduced their price objective for the stock from $17.00 to $16.00 in a research note on Tuesday, November 5th. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $21.67.
Shares of HALO traded up $0.24 during trading hours on Thursday, hitting $20.47. 18,416 shares of the company were exchanged, compared to its average volume of 1,185,855. The company has a market capitalization of $2.91 billion, a PE ratio of -36.52 and a beta of 1.86. The company has a debt-to-equity ratio of 0.04, a current ratio of 3.17 and a quick ratio of 2.83. The firm has a fifty day simple moving average of $18.69 and a 200-day simple moving average of $17.05. Halozyme Therapeutics has a one year low of $14.61 and a one year high of $20.36.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biotechnology company, engages in researching, developing, and commercializing novel oncology therapies in the United States, Switzerland, and internationally. Its human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.
Further Reading: What is the Dividend Aristocrat Index?
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.